Physician profile
Robert L Chaefsky
NPI 1679569420
$707.80
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $234 · 2022: $23.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $188.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $117.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $112.06 | 2019 | |
| Lundbeck LLC | $78.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.94 | 2019-2020 | |
| Alkermes, INC. | $44.98 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $34.05 | 2019 | |
| Vanda Pharmaceuticals INC. | $26.48 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $23.64 | 2019 | |
| Shire North American Group INC | $16.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chaefsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.